drugset / Trial / NCT01316107

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

NCT01316107

Phase 3 Completed 122 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and Nateglinide inhibitor in Japanese patients with type 2 diabetes mellitus.

Timeline

Start
2011-01-15
Primary completion
2012-10-19
Completion
2012-10-19

Drugs

EvaluationDrugModalityDoseRoute
Subject ipragliflozin Small molecule Oral
Background Nateglinide Small molecule Oral